Anglico: Clinical trial of injection ALK-N001 drug approved.

On April 27th, Anhui Kangli announced that its injectable ALK-N001 has obtained the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, allowing the product to conduct clinical trials for advanced solid tumors. Injectable ALK-N001 is a globally innovative tumor microenvironment-activating small molecule conjugate drug, and the company has obtained the rights to develop this drug in the licensed area through licensing agreements.